Equities Analysts Set Expectations for CTMX Q2 Earnings

CytomX Therapeutics, Inc. (NASDAQ:CTMX) – HC Wainwright decreased their Q2 2025 earnings estimates for shares of CytomX Therapeutics in a research report issued to clients and investors on Thursday, May 15th. HC Wainwright analyst M. Kapoor now expects that the biotechnology company will earn $0.02 per share for the quarter, down from their prior forecast of $0.20. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for CytomX Therapeutics’ current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for CytomX Therapeutics’ Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.02 EPS, FY2025 earnings at $0.23 EPS, Q1 2026 earnings at $0.01 EPS, Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.00 EPS and Q4 2026 earnings at ($0.02) EPS.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.09. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The company had revenue of $50.92 million for the quarter, compared to the consensus estimate of $35.42 million. During the same period last year, the firm posted $0.17 EPS.

A number of other equities research analysts also recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and set a $6.00 price objective (up previously from $5.00) on shares of CytomX Therapeutics in a research report on Monday, May 12th. Piper Sandler boosted their price objective on shares of CytomX Therapeutics from $2.50 to $5.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, StockNews.com raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, May 13th.

CytomX Therapeutics Stock Up 1.5%

Shares of NASDAQ:CTMX opened at $2.03 on Monday. CytomX Therapeutics has a fifty-two week low of $0.40 and a fifty-two week high of $2.55. The firm has a 50-day simple moving average of $0.82 and a 200 day simple moving average of $0.89. The company has a market cap of $163.66 million, a PE ratio of 11.94 and a beta of 1.11.

Institutional Trading of CytomX Therapeutics

Hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its position in CytomX Therapeutics by 288,736.3% in the 4th quarter. JPMorgan Chase & Co. now owns 811,630 shares of the biotechnology company’s stock valued at $836,000 after purchasing an additional 811,349 shares during the last quarter. Renaissance Technologies LLC lifted its position in CytomX Therapeutics by 32.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,346,800 shares of the biotechnology company’s stock valued at $1,387,000 after purchasing an additional 331,800 shares during the last quarter. Prudential Financial Inc. lifted its position in CytomX Therapeutics by 76.2% in the 4th quarter. Prudential Financial Inc. now owns 64,300 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 27,800 shares during the last quarter. Schonfeld Strategic Advisors LLC lifted its position in CytomX Therapeutics by 13.9% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 1,380,800 shares of the biotechnology company’s stock valued at $1,422,000 after purchasing an additional 169,000 shares during the last quarter. Finally, Prosight Management LP lifted its position in CytomX Therapeutics by 29.2% in the 4th quarter. Prosight Management LP now owns 3,905,000 shares of the biotechnology company’s stock valued at $4,022,000 after purchasing an additional 882,891 shares during the last quarter. 67.77% of the stock is currently owned by institutional investors.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.